TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16702006
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at an initial dose of 0.003 mg/kg/day for 4 weeks, increased to 0.006 mg/kg/day for 4 weeks, and then to 0.012 mg/kg/day for the last 16 weeks
Study: 7947061
Drug: Conventional dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressing and compression therapy
Study: 27787443
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab plus DHA (1,050 mg/day)
Study: 19653341
Drug: Imipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25 mg, allowed to double at week 2 if needed)
Study: 15113952
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (120 mg iron as ferrous sulfate and 0.5 mg folic acid)
Study: 15113952
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron supplementation (60 mg iron and 0.25 mg folic acid)
Study: 22888611
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron supplementation
Study: 11306774
Drug: Amantadine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (500 ml i.v. daily for 5 days)
Study: 9522320
Drug: cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyproterone acetate (5 mg p.o.)
Study: 9522320
Drug: nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: nomegestrol acetate (5 mg p.o.)
Study: 9522320
Drug: progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: progesterone (100 mg, vaginal cream)
Study: 7699945
Drug: HLBI-VCAP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLBI-VCAP combination therapy (Interferon-alpha + VCAP chemotherapy)
Study: 7699945
Drug: VCAP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCAP chemotherapy alone
Study: 27806875
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D3 supplementation
Study: 24687891
Drug: Continuous device-aided
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous device-aided drug delivery
Study: 22013099
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g alcohol/d
Study: 22013099
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol/d
Study: 17638583
Drug: GLOA (buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLOA (buprenorphine injection to the stellate ganglion)
Study: 17638583
Drug: SSB (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSB (saline injection to the stellate plus intramuscular buprenorphine)
Study: 8756806
Drug: Oxygen monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen monotherapy
Study: 8756806
Drug: NPPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPPV plus O2 therapy
Study: 1348473
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (20 mg daily)
Study: 2865921
Drug: High-dose ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketoconazole (800 mg/d)
Study: 2865921
Drug: Low-dose ketoconazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketoconazole (400 mg/d)
Study: 2865921
Drug: Both low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both low-dose and high-dose ketoconazole
Study: 2865921
Drug: Ketoconazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (both doses)
Study: 31290983
Drug: Targeted insulin-adherence
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted insulin-adherence interventions
Study: 25262177
Drug: IV hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV hydrocortisone (5 mg)
Study: 22953792
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including interactive training and a software programme for dose adjustment
Study: 20701547
Drug: Intraoperative analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative analgesics
Study: 18028738
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (150 mg/day for 5 days starting from day 3 of cycle)
Study: 15756629
Drug: Salmeterol-fluticasone combination
Normalized name: FLUTICASONE/SALMETEROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol-fluticasone combination (50 mcg salmeterol plus 500 mcg fluticasone, twice daily)
Study: 15756629
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (inhaled steroid 1,000 mcg BDP equivalent plus LABA and/or theophylline and/or montelukast)
Study: 11944382
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg twice daily (Group II)
Study: 11944382
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Group I)
Study: 28880361
Drug: Mini-pool intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-pool intravenous immunoglobulin (1 g/kg over 6 to 8 hours)
Study: 28880361
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous immunoglobulin (approximately 1 g/kg as a single dose)
Study: 28880361
Drug: No platelet-enhancing
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: No platelet-enhancing therapy (Control Group C)
Study: 26118558
Drug: Laboratory-based pathway
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory-based pathway with in-laboratory sleep study and CPAP titration
Study: 22960240
Drug: Individual mirror
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual mirror therapy
Study: 22960240
Drug: Group mirror
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group mirror therapy
Study: 19044299
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) administered to 53 patients in the immediate postoperative period
Study: 16575109
Drug: BCG in
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG in low dose (0.01 mg)
Study: 16575109
Drug: BCG in
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG in high dose (1.0 mg)
Study: 10894974
Drug: 1% colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% colchicine gel
Study: 10894974
Drug: Hydrophilic gel
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic gel (placebo)
Study: 8238148
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg) from 24 weeks' gestation until delivery
Study: 3807445
Drug: Pentazocine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (75 mg)
Study: 3807445
Drug: Codeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (100 mg)
Study: 2056362
Drug: Diazepam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.25 mg/kg)
Study: 23178661
Drug: Wuling capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling capsule
Study: 29971999
Drug: Intradermal needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needling combined with tuina
Study: 23662659
Drug: Static progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static progressive stretch orthosis with physical therapy
Study: 18559037
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in the other ear (control)
Study: 10522247
Drug: Buprenorphine (7.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (7.3 mg sublingual tablets)
Study: 10522247
Drug: Methadone (63
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (63 mg oral)
Study: 27688313
Drug: Pharmacological pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological pain treatments
Study: 27688313
Drug: Nonpharmacological pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological pain treatments
Study: 26101174
Drug: Amifampridine phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amifampridine phosphate salt (20 mg base equivalents per dose) under fed conditions
Study: 26101174
Drug: Amifampridine phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amifampridine phosphate salt (20 mg base equivalents per dose) under fasted conditions
Study: 26101174
Drug: Amifampridine phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amifampridine phosphate salt (20 mg base equivalents per dose)
Study: 25627992
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate (500 ml preload)
Study: 20678132
Drug: Immediately placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately placed implants in sockets without periapical pathology (test group)
Study: 20678132
Drug: Immediately placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately placed implants in sockets with periapical pathologies (control group)
Study: 19321811
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality cognitive behavior therapy (VRCBT)
Study: 30124753
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg daily, orally)
Study: 30124753
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine)
Study: 27799176
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg i.v. paracetamol
Study: 27799176
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml normal saline (placebo)
Study: 24249722
Drug: Thiazide diuretic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic-based therapy
Study: 20829700
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg/ml with metoclopramide 0.5 mg/ml and diphenhydramine 0.6 mg/ml (group 4)
Study: 20829700
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg/ml (group 1)
Study: 20829700
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg/ml with metoclopramide 0.5 mg/ml (group 2)
Study: 20829700
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg/ml with diphenhydramine 0.6 mg/ml (group 3)
Study: 18270560
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b Hiberix vaccine
Study: 6605890
Drug: Fentiazac suspension
Normalized name: fentiazac
DrugBank: Fentiazac (DB13217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentiazac suspension
Study: 31493105
Drug: Family-based exposure-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based exposure-focused treatment (FET)
Study: 25205641
Drug: Upper airway
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper airway stimulation via the hypoglossal nerve (therapy maintenance 'ON' group)
Study: 25205641
Drug: Upper airway
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper airway stimulation via the hypoglossal nerve (therapy withdrawal 'OFF' group)
Study: 21729466
Drug: Universal Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal Fe supplementation of 65 mg/d for two months (group II)
Study: 21729466
Drug: Universal anaemia
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal anaemia screening and treatment of anaemic women (group I)
Study: 18585508
Drug: Abciximab bolus-only
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus-only (0.25 mg/kg)
Study: 19753635
Drug: Abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab bolus + infusion (12 hours)
Study: 19753635
Drug: Not-randomized group
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not-randomized group (abciximab bolus and infusion)
Study: 17888214
Drug: Computerized administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized administration (PC)
Study: 17888214
Drug: Interviewer administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interviewer administration (IA)
Study: 15554742
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin gel
Study: 15554742
Drug: 0.1% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tretinoin microsphere gel
Study: 15554742
Drug: 0.1% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tazarotene gel (once every two days)
Study: 15554742
Drug: 0.1% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tazarotene gel (once daily)
Study: 11442615
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel sheeting (applied 48 hours after surgery)
Study: 11442615
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel sheeting (following scar revision procedure)
Study: 10958249
Drug: Bromocriptine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 1.25 mg + Haloperidol 3 mg
Study: 8032040
Drug: Glutaraldehyde inhalation
Normalized name: GLUTARALDEHYDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutaraldehyde inhalation challenge at 0.032 ppm
Study: 8032040
Drug: Glutaraldehyde inhalation
Normalized name: GLUTARALDEHYDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutaraldehyde inhalation challenge at up to 0.32 ppm for 10 min (second series)
Study: 2470577
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrocortisone
Study: 24963599
Drug: Equine‐assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine‐assisted therapy protocol (EAT), 16-week program, 2 hours of activity per week
Study: 9408700
Drug: Mesigyna (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate)
Study: 9408700
Drug: Cyclofem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate)
Study: 14561536
Drug: Ortho-Novum 1/35
Normalized name: Ortho-Novum 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho-Novum 1/35 (norethisterone 1 mg and ethinyl estradiol 35 microg)
Study: 1898892
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (gonadotropin followed by pulsatile GnRH)
Study: 1898892
Drug: Pure exogenous
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure exogenous follicle-stimulating hormone alone
Study: 6227542
Drug: Diprosalic Solution
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprosalic Solution (0.64 mg betamethasone‐dipropionate plus 20 mg salicylic acid)
Study: 6227542
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate solution (0.64 mg)
Study: 30036194
Drug: Regular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular exercise as an adjuvant treatment in myopathies
Study: 17148938
Drug: Valproate treatment
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate treatment for 6 weeks
Study: 15886473
Drug: HA in
Normalized name: ACALYPHA INDICA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA in combination with DOX (30-60 mg/m2)
Study: 15886473
Drug: HA in
Normalized name: ACALYPHA INDICA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA in combination with 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle)
Study: 15886473
Drug: HA/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA/chemotherapy
Study: 12070557
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg/day orally)
Study: 12070557
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (30 mg/day orally)
Study: 7596622
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (titrated from 0.1 to 0.3 mg/day)
Study: 30954691
Drug: 5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg of 3% saline (hypertonic group)
Study: 30954691
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg of 0.9% saline (isotonic group)
Study: 26141464
Drug: Preoperative eradication
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative eradication regimen: rabeprazole, amoxicillin, and clarithromycin before surgery
Study: 26141464
Drug: Postoperative eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative eradication regimen: rabeprazole, amoxicillin, and clarithromycin after postoperative day 8
Study: 11724129
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of gel containing 2% lidocaine
Study: 11724129
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of gel without lidocaine
Study: 11724129
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of gel containing 2% lidocaine
Study: 11724129
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of gel without lidocaine
Study: 9446253
Drug: G-CSF, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF, 2.5 micrograms/kg/day s.c. for the first 3 days followed by GM-CSF, 2.5 micrograms/kg/day s.c. for the last 3 days
Study: 9446253
Drug: G-CSF, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF, 2.5 micrograms/kg/day s.c. from the 8th day to the 13th day of cycle
Study: 8323356
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment for one week
Study: 30110706
Drug: 0.067 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.067 mg/kg/day r‐hGH for 12 months
Study: 30110706
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of no treatment followed by 0.067 mg/kg/day r‐hGH for 6 months
Study: 27997608
Drug: Peripheral Electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral Electrical Stimulation (PES) treatment (1.33Hz/16Hz burst mode), for 14 days
Study: 26098483
Drug: Fenugreek seeds
Normalized name: FENUGREEK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek seeds (10 g/d)
Study: 26098483
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g/d of wheat starch)
Study: 20182424
Drug: AM103 (50-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM103 (50-1000 mg single dose)
Study: 20182424
Drug: AM103 (50-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM103 (50-1000 mg once daily for 11 days)
Study: 20182424
Drug: AM103 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM103 (all doses)
Study: 11018854
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg/day (T100)
Study: 11018854
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg/day (T200)
Study: 9277651
Drug: Progesterone 45
Normalized name: progesterone 45 mg in 1.125 g VAGINAL GEL [Crinone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 45 mg vaginal gel (group A, n = 14)
Study: 9277651
Drug: Progesterone 90
Normalized name: progesterone 90 mg in 1.125 g VAGINAL GEL [Crinone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 90 mg vaginal gel (group B, n = 13)
Study: 9277651
Drug: Progesterone 180
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 180 mg vaginal gel (group C, n = 13)
Study: 9277651
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) administered for 28 days prior to progesterone treatment
Study: 27506771
Drug: Oral 35,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 35,000 IU/week vitamin D3
Study: 12674587
Drug: Antihypertensive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive and hypolipidemic drugs
Study: 12674587
Drug: Lowering blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering blood pressure below 140/90 mm Hg and LDL‐cholesterol below 3 mmol/l (or even < 2.6 mmol/l)